Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human (tested or 100% immunogen sequence identity)
Specificity and Use
SQSTM1 antibody was raised against synthetic peptide as a part of sequestosome-1 (ubiquitin-binding protein p62, p60, EBIAP) conjugated to immunogenic carrier protein has been used as the immunogen.
Specific for sequestosome-1.
Lyophilized. Centrifuge to remove any insoluble material
500 µl Sterile water
Maintain lyophilized and reconstituted antibodies at -20 °C for long term storage and at 2-8 °C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.
SQSTM1 Antibody, A170 Antibody, ORCA Antibody, OSIL Antibody, Paget disease of bone 3 Antibody, p60 Antibody, p62 Antibody, PDB3 Antibody, Sequestosome-1 Antibody, Ubiquitin-binding protein p62 Antibody, Oxidative stress induced like Antibody, p62B Antibody, ZIP3 Antibody, Sequestosome 1 Antibody, EBI3-associated protein p60 Antibody, EBIAP Antibody
Autophagy receptor that interacts directly with both the cargo to become degraded and an autophagy modifier of the MAP1 LC3 family. Required both for the formation and autophagic degradation of polyubiquitin-containing bodies, called ALIS (aggresome-like induced structures) and links ALIS to the autophagic machinery. Involved in midbody ring degradation. May regulate the activation of NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1.